We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 07, 2021

Effects of Dapagliflozin on Myocardial Function and Metabolism in Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Effects of 6 Weeks Treatment With Dapagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, on Myocardial Function and Metabolism in Patients With Type 2 Diabetes: A Randomized Placebo-Controlled Exploratory Study
Diabetes Obes Metab 2021 Feb 24;[EPub Ahead of Print], J Oldgren, S Laurila, A Åkerblom, A Latva-Rasku, E Rebelos, H Isackson, M Saarenhovi, O Eriksson, K Heurling, E Johansson, U Wilderäng, C Karlsson, R Esterline, E Ferrannini, J Oscarsson, P Nuutila

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading